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Abstract
The Glucocorticoid-Induced Tumor necrosis factor Receptor GITR, a member of the tumor necrosis factor receptor
superfamily, has been shown to be important in modulating immune responses in the context of T cell immunity. B
lymphocytes also express GITR, but a role of GITR in humoral immunity has not been fully explored. To address this
question, we performed studies to determine the kinetics of GITR expression on naı ¨ve and stimulated B cells and the
capacity of B cells to develop and mount antibody responses in GITR
2/2 mice. Results of our studies indicate that all mature
B cells express GITR on the cell surface, albeit at different levels. Expression of GITR on naı ¨ve mature B cells is upregulated by
BCR signaling, but is counteracted by helper T cell-related factors and other inflammatory signals in vitro. In line with these
findings, expression of GITR on germinal center and memory B cells is lower than that on naı ¨ve B cells. However, the
expression of GITR is strongly upregulated in plasma cells. Despite these differences in GITR expression, the absence of GITR
has no effect on T cell-dependent and T cell-independent antibody responses to model antigens in GITR
2/2 mice, or on B
cell activation and proliferation in vitro. GITR deficiency manifests only with a slight reduction of mature B cell numbers and
increased turnover of naı ¨ve B cells, suggesting that GITR slightly contributes to mature B cell homeostasis. Overall, our data
indicate that GITR does not play a significant role in B cell development and antibody responses to T-dependent and
independent model antigens within the context of a GITR-deficient genetic background.
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Introduction
Through the interplay of receptors and ligands, tumor necrosis
factor superfamily (TNFSF) members play a role in numerous
biological processes. By affecting cell signaling, survival, prolifer-
ation and/or differentiation, TNFSF members regulate the
immune system resulting in either beneficial or harmful effects
[1]. One such protein is TNFRSF18 or glucocorticoid-induced
TNF receptor family-related gene (GITR), which shares many
characteristics with some other TNFRSF members, namely
OX40, 4-1BB and CD27 [2]. Like those TNFSF receptors, GITR
only interacts with one ligand, GITRL [3], which is prevalently
expressed by professional antigen presenting cells such as dendritic
cells, macrophages and B cells [4,5].
The function of GITR has been studied mainly in T cells, which
express GITR constitutively. Regulatory T cells express the
highest level of GITR. However, antigen receptor stimulation of
naı ¨ve conventional T cells leads to GITR upregulation to levels
observed in regulatory T cells [6,7,8,9]. Studies in T cells suggest
that GITR plays an important role in modulating T cell responses.
Deletion of GITR, or use of reagents that block GITRL, prevent
optimal proliferation of T cells in response to CD3 stimulation
with or without CD28 co-stimulation [5,8], suggesting that GITR
may function to improve the magnitude of T cell responses. In
fact, GITR is required for the survival of antigen-specific CD8 T
cell clones and their expansion in response to influenza infection
[10]. Moreover, stimulation of effector T cells through GITR
provides them with resistance to suppression by regulatory T cells
[5], while GITR stimulation of regulatory T cells inhibits their
suppressive function [6,7]. Thus, GITR operates in different ways
to promote T cell responses. In fact, in vivo, GITR was shown to
enhance immune responses to tumors and viral pathogens, but
also contribute to the development of autoimmune diseases
[7,11,12,13,14].
Hematopoietic cell types other than T cells, specifically
macrophages and B cells, have been shown to express low levels
of GITR [7]. However, the functional role of GITR in these cells
has not been explored. In this study, we investigated the regulation
of GITR expression on B cells and its potential function in B cell
development and B cell response.
Our studies demonstrate that B cells express GITR starting at
the transitional stage of B cell development. GITR expression is
positively modulated by BCR signaling and negatively regulated
by factors commonly provided by helper T cells. Despite the fact
that all B cells express GITR, our data indicate that in the context
of a whole GITR-deficient genetic background, this TNFSF
receptor does not play a significant role in B cell development, B
cell proliferation in response to antigen receptor stimulation and T
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dependent and T cell-independent model antigens in vivo. The
absence of GITR manifests only with a slight reduction of mature
B cell numbers and increased B cell turnover, suggesting that
GITR plays a small role in B cell homeostasis.
Results
B cell expression of GITR
Previous studies reported low levels of GITR expression on
mature B cells [7]. To determine when GITR is first expressed on
developing B cells and its level on different B cell subsets, bone
marrow and spleen B cells of wild-type mice were analyzed by flow
cytometry for the expression of GITR and B cell developmental




cells displayed GITR slightly above antibody isotype control
(Fig. 1A), while pro-B cells and pre-B cells had no detectable
GITR expression (data not shown). GITR was expressed on all
bone marrow IgM
highIgD
low and spleen B220
+CD24
high transi-
tional B cells, although these cell populations displayed large
variation in expression level (Fig. 1A). GITR expression was
further increased, on average, on bone marrow recirculating
IgM
lowIgD
high mature B cells, which displayed levels similar to
those of splenic B220
+CD24
low mature B cells (Fig. 1A). Despite
the detection of GITR on naı ¨ve B cells, this level was considerably
lower than that on naı ¨ve CD4
+ T cells, which were used as positive
control (Fig. 1A). GITR expression was also evaluated on antigen
activated B cells (i.e., germinal center and memory B cells and
plasma cells) that arise in response to environmental antigens in
mice maintained in specific-pathogen free conditions (Fig. 1A).




+) and memory (B220
+IgG
+) B cells exhibited
lower levels of GITR that were similar to those of bone marrow
immature B cells (Fig. 1A). Antigen-specific germinal center B cells
that were analyzed 7 and 15 days following immunization with a
T-dependent antigen also expressed GITR at lower levels than
naı ¨ve B cells (Fig. 1B). Expression of GITR was upregulated on
B220
2CD138
+ plasma cells, which expressed the highest level
among the B cell subsets even when the difference in cell size was
taken into account (Fig. 1A, and data not shown). Lymph node B
cells expressed GITR at levels similar to those of splenic B cells
(data not shown).
These data indicate that GITR is expressed constitutively on all
B cells starting at the transitional B cell stage although its level
varies during B cell development and within B cell subsets.
BCR stimulation enhances GITR expression on B cells
LPS was previously shown to induce GITR upregulation on B
cells [7]. It is also known that T cells upregulate GITR upon CD3
stimulation [6,7,8,9]. To test whether stimulation of B cells via the
B cell receptor (BCR) could similarly induce GITR upregulation,
we treated spleen B cells with an optimal concentration (10 mg/ml)
of F(ab9)2 anti-IgM polyclonal antibodies for up to 72 h and
analyzed GITR levels by flow cytometry at different time points.
In fact, B cells stimulated via their BCR for 48 h upregulated
GITR to a much greater extent, on average, than B cells
stimulated with 20 mg/ml of LPS (Fig. 2A). GITR upregulation
was initially observed on some B cells after 8 hours of BCR
stimulation (Fig. 2B). By 24 hours, GITR was upregulated on
average 5-fold on all B cells and reached maximum levels at
48 hours (Fig. 2B). CD69 and CD86, two well-described B cell
activation markers, were analyzed alongside GITR to confirm B
cell activation and compare the kinetics of upregulation. As shown
in Fig. 2B, expression of CD69 and CD86 was already increased
on all B cells after 8 hours of BCR stimulation, indicating that
their upregulation preceded that of GITR. Conversely, GITR
expression after 72 hours of BCR stimulation was maintained at
levels comparable to those at 48 hours while CD69 was
downmodulated (data not shown).
These data indicate that BCR stimulation of B cells, similar to
TCR stimulation of T cells, promotes higher expression of GITR,
which is sustained for at least 72 hours.
Increased expression of GITR on BCR-stimulated B cells is
due to de novo transcription and translation, and is partly
dependent on NFAT signaling
To assess whether the increase in GITR levels mediated by
BCR stimulation on B cells was due to either de novo synthesis or
the presence of pre-formed pools of GITR, we used actinomycin
D and cycloheximide to inhibit gene transcription and translation,
respectively. For these studies, B cells were evaluated after
24 hours of culture because the transcription/translation inhibi-
tors caused extensive cell death at a later time. A drawback of the
short time cultures, however, was that GITR was not upregulated
to the maximum level (Fig. 2B). Additionally, we found that
DMSO, used as a diluent for the inhibitors and added to control
cultures, inhibited somewhat GITR expression on B cells.
Nevertheless, results of these studies show that addition of either
actinomycin D or cycloheximide during BCR stimulation of B
cells for 24 hours prevented the upregulation of GITR (Fig. 2C).
Due to the variability in GITR expression on BCR-stimulated B
cells, this difference was not statistically significant (p=0.07), but
inhibition of GITR upregulation was reproducibly observed in all
experiments (n=3). Importantly, actinomycin D and cyclohex-
amide did not alter upregulation of CD69 on BCR-stimulated B
cells (data not shown), similarly to what was previously observed in
T cells [15], indicating that inhibition of GITR upregulation was
not due to cell stress or death. These data indicate that GITR
upregulation necessitates de novo gene transcription and translation,
potentially explaining why it requires 8–24 hours for higher GITR
expression to ensue.
Since BCR signaling modulates GITR expression, we wanted to
assess which downstream signaling pathway might be involved in
GITR regulation. Zhan et al. [9] has reported that GITR
expression is modulated by the NFAT signaling pathway in T
cells. To determine whether NFAT regulates GITR expression on
B cells, BCR-stimulated spleen B cells were treated with
cyclosporin A (CsA), an NFAT pathway inhibitor. Treatment of
B cells with CsA prevented maximum upregulation of GITR on
BCR-stimulated B cells and this difference was statistically
significant (Fig. 2D). CD86 levels, in contrast, were not affected
by CsA (Fig. 2D), indicating intact cell function. Our data,
therefore, suggest that NFAT signaling promotes GITR upregula-
tion on BCR-stimulated B cells.
Helper T cell factors inhibit GITR upregulation induced by
BCR signaling on B cells
The upregulation of GITR expression mediated by BCR
signaling on naı ¨ve B cells contrasted the observation that germinal
center and memory B cells, which are antigen-activated cells,
expressed GITR at levels lower than those of naı ¨ve B cells (Fig. 1).
Given these contrasting findings, we next explored how GITR
levels are modulated by T cell factors, with the hypothesis that
helper T cell-specific factors might decrease GITR expression. To
this end, we utilized anti-CD40 antibodies and/or recombinant
cytokines that recapitulate signals normally provided by T cells
and other cells during Th1 and Th2 responses. Hence, 15 mg/ml
Analysis of GITR Function in Mouse B Cells
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IFNc or 1000 U/ml of IFNa were added to B cell cultures, with or
without BCR stimulation (Fig. 3 and data not shown). This level of
CD40 stimulation on B cells increased GITR expression albeit to a
lower level than that induced by BCR stimulation (Fig. 3A, left
panel). The induction of GITR expression by CD40 was not
mediated via the NFAT pathway, as the addition of CsA to anti-
CD40-treated B cells did not prevent GITR upregulation (Fig. 3A,
right panel). In contrast to the positive effect of anti-CD40 on
GITR expression, IL-4, IFNc, or IFNa alone did not alter GITR
levels on B cells after 48 hours of treatment (Fig. 3B). Interestingly,
when anti-CD40 antibodies, IL-4, IFNc, or IFNa were added to B
cells in combination with BCR (anti-IgM) stimulation, these
signals inhibited maximum GITR upregulation compared to BCR
stimulation alone (Fig. 3B). Thus, our results indicate that some
helper T cell components, at least at the doses used here, block
maximum GITR upregulation observed in response to a BCR
signal on B cells. This effect was unique to GITR, as CD69 and
CD86 levels increased as expected (data not shown). Moreover,
IL-4, IFNc, and IFNa were also able to inhibit GITR
upregulation mediated by CD40 stimulation on B cells (Fig. 3C).
These findings may explain the observation that germinal center
and memory B cells express low levels of GITR, as these B cell
subsets are the result of a cognate B cell-T cell interaction.
These data suggest that while GITR is upregulated by BCR
signaling and may function on B cells receiving signal 1 (antigen
binding), the expression and signaling of this TNF family receptor on
B cells may be negligible in the context of a T-dependent response.
B cell development in GITR-deficient mice
The differential expression of GITR by B cell subsets and its
regulation in the context of BCR and cytokine receptor
Figure 1. B cells express GITR starting at the transitional stage of development. (A) Bone marrow and spleen cells from wild-type (129S1)
mice were analyzed ex vivo by flow cytometry for the expression of indicated markers. Live cells in dot plots were gated as indicated on top.
Histograms depict GITR expression on B cells in subsets gated as shown in the dot plots in top panel. Expression of GITR on gated CD4
+ T cells is
shown as a positive control for GITR staining. Rat IgG2b was used as an isotype control for GITR staining. Data are representative of 3 independent
experiments. Similar GITR expression was observed on B cells from BALB/c mice (data not shown). (B) GITR
+/+ (BALB/c) mice were immunized i.p. with
100 mgN P 39-CGG in Alum. At days 4, 7, and 15 post immunization, spleen cells were harvested from 2 immunized and 2 nonimmunized (naı ¨ve) mice
at each point and analyzed for GITR expression on germinal center B cells reactive with NP. The dot plots show NP and PNA binding on B220
+PNA
high
gated B cells from one naive (left panel) and one immunized (right panel) mouse at day 7. There were no NP
+ germinal center B cells at day 4, and





high germinal center B cells. GITR
expression on NP
+ germinal center B cells of one mouse at day 7 (black intact line) and one mouse at day 15 (gray intact line) following immunization
are shown compared to those on total B220
+PNA
2 B cells (dark-shaded histogram and dashed black line) in respective animals and on lymphocytes
of one GITR
2/2 mouse (light-shaded histogram).
doi:10.1371/journal.pone.0031632.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31632Figure 2. BCR stimulation enhances GITR expression on B cells. B cells were purified from the spleen of BALB/c mice by negative selection
and all B cell cultures were performed in the presence of 4 ng/ml of BAFF to sustain cell survival. (A) Representative GITR expression on B cells
cultured for 48 h in medium alone (gray line) or in the presence of either 10 mg/ml F(ab9)2 anti-IgM antibodies (dashed line) or 20 mg/ml LPS (intact
black line). (B) B cells were cultured in either medium alone (dashed line) or with 10 mg/ml F(ab9)2 anti-IgM antibodies (intact line). Expression of GITR,
CD69 and CD86 were analyzed at 8, 24 and 48 h of culture. The bar graph represents average GITR mean fluorescent intensity (MFI) on B cells
cultured with medium or anti-IgM antibodies for 48 h from 3 independent experiments. **p#0.002, n=3. (C) B cells were stimulated in culture for
24 h with 10 mg/ml F(ab9)2 anti-IgM antibodies without (dashed line) or with 0.1 mM actinomycin D (ActD) to inhibit transcription, or 2 mM
cycloheximide (Chx) to inhibit protein synthesis (intact black line). Gray line indicates GITR expression on cells cultured in medium alone. The diluent
DMSO (0.2–0.4%) was present in all cultures. The bar graph represents average GITR MFI on B cells cultured with medium, anti-IgM antibodies, or anti-
IgM antibodies with the indicated inhibitor from 3 independent experiments. Differences were not statistically significant, but were observed in all
three independent experiments. (D) GITR (left) and CD86 (right) expression on B cells cultured for 48 h with 10 mg/ml F(ab9)2 anti-IgM antibodies
alone (dashed line) or in the presence of 0.2 mM of cyclosporin A (CsA, intact black line). Expression on B cells cultured in medium alone (gray line) is
shown for comparison. The bar graph represents average GITR MFI on B cells cultured with medium, anti-IgM antibodies, or anti-IgM antibodies with
CsA from 3 independent experiments. *p#0.05, n=3. All histograms represent live, B220
+ lymphoid cells. Isotype control staining for GITR (light
shaded histogram) is shown in (B) and (C) and it was similar on stimulated or nonstimulated cells (data not shown). Data are representative of 2–6
independent experiments.
doi:10.1371/journal.pone.0031632.g002
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development and/or function. To begin to evaluate GITR
function in B cells, we examined whether the absence of GITR
affects B cell development. Thus, we enumerated B cells at all
stages of development from pro-B cells to naı ¨ve mature B cells in
GITR
2/2 [16] and control (129S1) mice. There was a small but
significant reduction of pre-B cells in GITR
2/2 mice, which did
not significantly affect immature and transitional T1 B cell
numbers (Fig. 4). Nonetheless, GITR
2/2 mice displayed a
significant, albeit small, reduction of transitional T2 and mature
B cell numbers (Fig. 4). In particular, all mature B cell subsets
analyzed, including the recirculating B cell population in the bone
marrow and the follicular and marginal zone B cell subsets of the
spleen, were similarly decreased in GITR
2/2 mice relative to
control animals (Fig. 4). Thus, while GITR is not required for
early B cell development, it appears to play a small role in the
generation and/or maintenance of mature B cells.
GITR expression and signaling are not necessary for B cell
costimulation and proliferation in vitro
To further assess the role of GITR in B cell function, we asked
whether GITR acts as a costimulatory molecule during B cell
activation. To this end, splenic B cells were stimulated in vitro with
a suboptimal concentration (2 mg/ml) of anti-IgM antibodies in
the presence or absence of recombinant GITR ligand (GITRL).
The functionality of the GITRL reagent was confirmed by its
ability to increase proliferation of wild-type, but not GITR
2/2,
CD4
+ T cells (data not shown). A suboptimal concentration of
anti-IgM was used to ensure that the BCR signaling alone did not
override possible effects induced by GITR signaling. B cell
activation was evaluated by the expression of the activation
markers CD69 and CD86. Our results show that addition of
GITRL to B cells, whether alone or with anti-IgM antibodies, did
not lead to increased expression of CD69 and CD86 (Fig. 5A).
Similar results were obtained using different concentrations (0.1,
0.5 or 10 mg/ml) of anti-IgM antibodies (data not shown).
Previous studies have shown that GITR is important for the
proliferation of T cells in response to CD3 stimulation [5,8,16]. To
test if GITR also affects B cell proliferation, we labeled total spleen
cells from GITR
2/2 and control mice with CFSE and cultured
them for four days with or without BCR and co-receptor
stimulation. We reasoned that some spleen cells expressed GITRL
in these cultures, providing signaling function to GITR on B cells,
although we were unable to detect GITRL expression using
commercial and non-commercial antibodies (data not shown).
Therefore, to further ensure GITR signaling, agonistic anti-GITR
antibodies [7] were added to some cell cultures. GITR-deficient B
cells proliferated to the same extent as wild-type B cells when
treated with 10 mg/ml anti-IgM and/or 15 mg/ml anti-CD40
antibodies, or with anti-IgM together with IL-4 (Fig. 5B, top and
bottom panels). Additionally, stimulation of wild-type B cells with
agonistic anti-GITR antibodies did not aid in cell proliferation
Figure 3. Helper T cell factors inhibit GITR induction on BCR-stimulated B cells. B cells were purified from the spleen of wild-type BALB/c
mice by negative selection and used for in vitro analyses. All B cell cultures were performed in the presence of 4 ng/ml of BAFF to sustain cell survival.
(A) GITR expression on B cells cultured for 48 h in medium alone, with 2 mg/ml F(ab9)2 anti-IgM antibodies (gray line, left panel), 15 mg/ml anti-CD40
antibodies (dashed line, left and right panels), a combination of anti-IgM and anti-CD40 antibodies (intact black line, left panel), or a combinationo f
anti-CD40 antibodies and 0.2 mM CsA (intact black line, right panel). (B) GITR expression on B cells cultured for 48 h in medium alone (filled
histogram), 2 mg/ml F(ab9)2 anti-IgM antibodies (gray line), 50 ng/ml IL-4, 100 (not shown) and 1000 U/ml IFNc, 100 (not shown) and 1000 U/ml IFNa
(dashed line) or a combination of anti-IgM antibodies and cytokines (intact black line) as indicated. There was no difference between 100 and 1000 U/
ml of IFNc and IFNa (data not shown). Isotype control staining for GITR (light shaded histogram) is shown in (A) and (B) and it was similar on
stimulated or nonstimulated cells (data not shown). (C) GITR expression on B cells cultured with 15 mg/ml anti-CD40 antibodies alone (dashed line) or
in combination with 50 ng/ml IL-4, 1000 U/ml IFNc, or 1000 U/ml IFNa (intact line), as indicated. Note that the isotype control antibody staining was
included in all analyses but omitted in plots that display more than 3 samples for clarity.
doi:10.1371/journal.pone.0031632.g003
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GITR
+/+ (129S1 strain, white bars) and GITR
2/2 (black bars) mice were analyzed ex vivo by flow cytometry to determine the numbers of B cells at
different developmental stages. The following B220







2), transitional B (IgM
highIgD
low) and mature/recirculating B (IgM
lowIgD
high) cells. The following B220
+ B cell subsets were defined
in the spleen: transitional T1 (CD93
+IgM
+CD23
2), transitional T2 (CD93
+IgM
+CD23
+), transitional T3 (CD93
+IgM
lowCD23
+), follicular (FO, CD1d
2/
lowCD21
+), and marginal zone (MZ, CD1d
highCD21
high). n=10 from 5 independent experiments. Error bars represent SD; *p,0.05.
doi:10.1371/journal.pone.0031632.g004
Figure 5. GITR expression and signaling do not alter B cell activation and proliferation. (A) B cells were purified from the spleen of wild-
type BALB/c mice by negative selection and cultured for 48 h in medium alone (filled histogram) or in the presence of 1 mg/ml GITRL (gray line), 2 mg/
ml F(ab9)2 anti-IgM antibodies (dashed line) or a combination of these reagents (intact black line). All B cell cultures were performed in the presence
of 4 ng/ml of BAFF to sustain cell survival. Histograms indicate CD69 (left) and CD86 (right) expression on live B220
+ lymphocytes. Data are
representative of 3 independent experiments. (B) Total spleen cells from GITR
+/+ (129S1 strain) and GITR
2/2 mice were purified over a Ficoll gradient,
labeled with CFSE and cultured for 4 days. Cultured cells were either left untreated or stimulated with 10 mg/ml F(ab9)2 anti-IgM antibodies, 15 mg/ml
anti-CD40 antibodies, a combination of anti-IgM and anti-CD40 antibodies, or a combination of anti-IgM antibodies and 50 ng/ml IL-4, as indicated at
the top. All B cell cultures were performed in the presence of 4 ng/ml of BAFF to sustain cell survival. Cells from GITR-sufficient mice were treated as
stated above in the presence or absence of 10 mg/ml anti-GITR agonistic antibodies (DTA-1 clone). Histograms represent CFSE dilution in live, B220
+ B
lymphocytes. Numbers represent frequency of dividing (CFSE
low) cells in the population. Data are representative of 2 independent experiments.
doi:10.1371/journal.pone.0031632.g005
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survival were observed in GITR
2/2 B cells (data not shown).
Overall, these data indicate that GITR does not function as a
co-stimulatory receptor in B cell activation and proliferation.
GITR-deficient mice respond normally to T cell-
dependent and T cell-independent model antigens in
vivo
Antibody production is one of the main functions of B cells. We
tested whether GITR affects antibody production by measuring
first total levels of Ig isotypes in GITR
2/2 and control mice. As
shown in Fig. 6A, total levels of IgM, IgG1, IgG2a and IgE were
normal in GITR
2/2 mice, despite a slight reduction of mature B
cell numbers (Fig. 4), while those of IgG2b were slightly depressed.
Since BCR signaling and T cell-like help modulated GITR
levels on B cells, we next tested whether GITR affects B cell
responses to T-independent (TI) and T-dependent (TD) antigens.
To examine TI responses, mice were immunized with a model TI
type 2 antigen, the hapten NP conjugated to Ficoll (NP-Ficoll).
Sera were collected prior to immunization and at days 4 and 7
after immunization to measure NP-specific IgM and IgG3, the
predominant isotypes produced in response to this antigen. Pre-
immune and day 4 NP-specific IgM levels were slightly higher in
GITR
2/2 mice compared to wild-type levels (p=0.0002 and 0.01,
respectively), while day 7 levels were comparable between the two
groups (Fig. 6B). NP-specific IgG3 levels were similar at all time
points measured. Thus, GITR-deficient mice mount a relatively
normal response to NP-Ficoll immunization.
To evaluate the role of GITR in T-dependent antibody
responses, GITR
2/2 and control mice were immunized with a
TD model antigen, NP conjugated to chicken gamma globulin
(NP-CGG) in Alum, which is known to induce predominantly the
IgG1 isotype. NP-specific IgM, IgG1, and IgG2a levels were
slightly higher in GITR
2/2 mice at 7 and/or 14 days of the
immune response, while IgG2b levels were similar in both groups
(Fig. 6C). Moreover, immunization of mice with a combination of
NP-CGG and poly(I:C) resulted in similar NP-specific (and CGG-
specific) IgM, IgG2b and IgG2a, and lower IgG1 antibody
responses in GITR-deficient relative to GITR-sufficient mice (data
not shown), suggesting that the small differences observed
following NP-CGG/Alum immunization were not reproducible.
Additionally, antibody differences observed during NP-CGG/
Alum response were not maintained over time, as 79 days after
immunization the mice exhibited similar levels of NP-specific Ig
isotypes.
The amount of high affinity NP-specific IgG1 antibodies in
GITR
2/2 mice at day 14 of the TD-response, as measured on
ELISA plates coated with low avidity antigen, was also normal
(data not shown), indicating normal affinity maturation at this time
point. Our results, therefore, indicate that GITR-deficient mice
mount a normal primary immune response to TI and TD model
antigens.
To study the effect of GITR on secondary TD responses, mice
that were previously immunized with NP-CGG in Alum, were
boosted with a second NP-CGG immunization in the absence of
adjuvant 178 days after the primary immunization. NP-specific
IgG1, IgG2b and IgG2a levels were measured at 3, 7 and 14 days
after boosting. The memory response was comparable between
GITR-deficient and GITR-sufficient B cells (Fig. 6D).
Overall, these data indicate that GITR is not required for TI
and TD antibody responses to the model NP antigens.
Furthermore, GITR does not affect memory antibody responses
to the TD antigen NP-CGG.
GITR-deficient B cells display normal abilities in entering
the antigen-selected B cell populations in GITR
2/2 mice
When naı ¨ve mature B cells undergo a productive antigen
response, they undergo further differentiation into antigen-selected
B cell subsets, such as germinal center and memory B cells and
plasma cells. To determine whether GITR affects the antigen-
mediated differentiation of B cells, groups of GITR
2/2 and
control mice were fed BrdU in drinking water. The frequency of
BrdU
+ cells in the germinal center, memory and plasma cell
populations were measured after one or two weeks of BrdU
treatment. Since antigen-mediated activation of B cells promotes
cell proliferation and, therefore, BrdU incorporation, this
methodology can be used to determine the kinetics of antigen-
selected B cells in vivo [17]. One week after BrdU treatment, the
frequency of BrdU
+ cells in the germinal center, memory, and
plasma cell populations was 40% to 90%, depending on the
population (Fig. 7A). This high frequency reflected the fact that the
entry of B cells into these subsets requires cell proliferation. In fact,
the frequency of BrdU
+ B cells in the naı ¨ve B220
+ B cell
population was only approximately 5–10% (Fig. 7A), in line with
previous reports [18,19,20]. GITR
2/2 and control mice displayed
the same frequency of BrdU
+ cells in the germinal center,
memory, and plasma cell populations of the spleen, and plasma
cell population of the bone marrow (Fig. 7A). Data collected after
two weeks of BrdU feeding were similar to those at the end of week
one (data not shown). These data suggest that antigen-selection
and terminal differentiation of B cells are not affected in mice
lacking GITR. However, the frequency of BrdU
+ cells in the naı ¨ve
B220
+ B cell compartment was significantly higher in GITR
2/2
than in control mice (Fig. 7A), indicating a higher turnover of
naı ¨ve B cells in the absence of GITR, and correlating with reduced
numbers of mature B cells (Fig. 4).
If GITR function in B cells is subtle, it might be difficult to note
differences in intact GITR
2/2 mice where all cells lack GITR
expression. To address this issue, we tested how GITR-deficient B
cells would function in competition with GITR-sufficient cells. To
this end, we generated mixed bone marrow chimeras with
GITR
2/2 and GITR
+/+ cells congenic at the CD45 locus
(Fig. 7B). Bone marrow cells from GITR-deficient mice
(GITR
2/2, CD45.2) were mixed with B6.SJL bone marrow cells
(GITR
+/+, CD45.1) and injected into lethally irradiated B6
recipients. Control chimeras received a mix of bone marrow cells
from wild-type 129S1 mice (GITR
+/+, CD45.2) and B6.SJL. Bone
marrow, spleen and lymph nodes were analyzed by flow cytometry
to determine the size of CD45.2 B cell subsets, from the pro-B cell
to the plasma cell stages of B cell differentiation (Fig. 7C). Bone
marrow cells were mixed at a 3:1 ratio favoring B6.SJL cells
because seeding and growth of 129S1 hematopoietic stem cells is
superior to that of B6 cells. Nevertheless, 129S1 hematopoietic
cells still dominated the recipient mice. In addition, the frequency
of CD45.2 cells was slightly higher at the beginning of B cell
development (pro-B cells) in GITR
+/+ than in GITR
2/2
chimeras. Furthermore, the frequency of CD45.2 cells was not
perfectly maintained during B cell differentiation, making it
difficult to compare the two groups of mice. In spite of these issues,
the frequency of CD45.2 B cells appeared to follow a similar
pattern in both groups of chimeras (Fig. 7C). To better compare
the two groups, we measured the fold changes of the CD45.2 B
cell frequency in mature and antigen-selected B cell populations of
the spleen relative to that of the immature/transitional (CD24
high)
B cell population in each mouse within the two groups (Fig. 7D).
The only significant difference was in the follicular B cell
population, which was slightly decreased in GITR
2/2 chimeras
(Fig. 7D). This result, therefore, was in line with the reduced
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(Fig. 4) and the increased BrdU incorporation in B220
+ cells
(Fig. 7A).
Together, these data indicate that the absence of GITR does
not hinder early B cell development, but it causes a small defect in
the size of the follicular naı ¨ve B cell compartment. This defect does
not affect further differentiation of B cells into antigen-selected B
cell subsets, such as memory B cells and plasma cells.
Discussion
This study was performed to determine whether the TNF family
receptor GITR plays a role in basic B cell functions. We found
that expression of GITR on mature B cells is upregulated by BCR
signaling and downregulated by factors commonly provided by
helper T cells. In spite of this, the absence of GITR had only
minimal effects on mature B cell numbers, while it did not affect
antibody responses to model antigens, or B cell activation and
proliferation. These findings indicate that GITR does not play a
significant role in B cell development and antibody responses in
GITR-deficient mice.
We show that GITR is expressed at low levels on the surface of
resting mature B cells, approximately 10-fold lower than those on
naı ¨ve CD4 T cells. BCR stimulation, however, increases GITR
expression on mature B cells by at least 10-fold within 24 hours.
Thus, on BCR-stimulated B cells, GITR reaches levels compara-
ble to those of naı ¨ve CD4 T cells. Like BCR stimulation on B cells,
TCR stimulation on T cells also leads to upregulation of GITR by
approximately 10-fold [6,7,8,9]. Therefore, it appears that a
common signaling pathway downstream of antigen receptors in
both B and T cells leads to upregulation of GITR. Based on our
experiments involving transcription and translation inhibitors, we
conclude that the increase in GITR surface levels on BCR-
stimulated B cells results from de novo gene transcription, which is
perhaps the reason why maximum surface GITR levels are
achieved by 24–72 hours, and not by 8 hours following antigen
receptor stimulation.
In T cells, GITR upregulation was shown to be inhibited by
NFAT signaling [9]. In contrast, we found that in B cells,
inhibition of the NFAT pathway by CsA prevented maximum
GITR upregulation following BCR stimulation. This suggests that
NFAT promotes, and does not inhibit, GITR expression in B cells.
We explain this difference by the fact that Zhan et al. determined
the effect of NFAT on GITR expression on T cells stimulated with
ionomycin, and not via the TCR [9]. In fact, when we analyzed
GITR expression on CD3-stimulated T cells in the presence of
CsA, we found that GITR upregulation required NFAT signaling
(data not shown). In contrast, upregulation of GITR on T cells
stimulated with ionomycin was increased by CsA as previously
reported [9], but only when a low ionomycin concentration
(200 ng/ml) was used (data not shown). NFAT inhibition was
unable to completely suppress GITR expression on BCR-
stimulated B cells, suggesting that additional molecular pathways
control Tnfrsf18 gene transcription. Candidate pathways may be
those signaling via NF-kB and JNK, which have been additionally
suggested to promote GITR expression in T cells [9].
Despite the fact that BCR signaling promotes GITR upregula-
tion on B cells, neither GITR stimulation nor GITR-deficiency
modulated expression of activation markers and proliferation of B
cells stimulated with anti-IgM antibodies and additional stimuli.
These findings suggest that GITR does not function as a
costimulatory molecule for BCR signaling. GITR-deficient B cells
in intact GITR
2/2 mice and in mixed bone marrow chimeras
displayed only a minor but consistent defect at the naı ¨ve mature
cell stage. Namely, we observed slight, but significant, reduced
numbers of GITR-deficient mature B cells. Furthermore, we
observed a higher frequency of BrdU
+ resting B cells in the spleen
of GITR
2/2 mice relative to control mice fed BrdU for one or two
weeks. A higher frequency of BrdU
+ B cells entering the peripheral
mature B cell population within this timeframe suggests a reduced
lifespan and an increased cell turnover. These findings support the
idea that GITR slightly contributes to the survival of naı ¨ve mature
B cells and to their homeostasis. A similar role of GITR on
CD4
+CD25
+ T cell homeostasis and the survival of antigen
activated CD8 T cells have been previously reported [5,10].
GITR deficiency did not translate into defects in antibody
responses to T-dependent and T-independent model antigens and
entry of B cells into the antigen-activated cell populations. If GITR
were important for the survival of antigen activated B cells, we
expected to find a reduced BrdU incorporation in the B cell
memory and plasma cell populations, a result we did not observe.
A potential explanation for the lack of effects of GITR deficiency
on B cell responses might be that GITR is not upregulated (or
perhaps is downregulated) on activated B cells in vivo in the
presence of various inflammatory stimuli. In fact, GITR was
minimally expressed on antigen-activated B cells that had been
exposed to helper T cell factors and inflammatory cytokines in vitro,
and it was also poorly expressed on germinal center and memory
B cells ex-vivo. Thus, activated B cells in the context of an intact
immune system may be undistinguishable from GITR-deficient B
cells in relation to GITR expression and, therefore, response. It
has been reported that GITR stimulation greatly improves
humoral responses to ovalbumin and hemagglutinin in vivo,
potentially by increasing Th1 and Th2 cytokine production by
T cells [21]. Based on this latter study, we anticipated finding a
reduced antibody response to NP-CGG in GITR-deficient mice, a
result we did not observe. These apparently discordant results may
indicate that the role of GITR in immune responses depends on
the type of antigen and adjuvant. Alternatively, the effect of GITR
deficiency on B cells might be masked by its absence on other cell
types in GITR-deficient mice (as observed for CD8 T cells, [10])
or might manifest only in certain genetic backgrounds. Such issues
could be addressed by analyzing bone marrow chimeras in which
only B cells lack GITR and by backcrossing GITR-deficient mice
into other genetic backgrounds, respectively.
Another possible explanation for the minimal effects of GITR
deficiency on B cells is that the function of GITR is shared by
other TNF-family receptors [13]. Although our studies cannot
Figure 6. GITR-deficient mice mount relatively normal antibody responses to model antigens. (A) Total serum levels of IgM, IgG1, IgG2b,
IgG2a and IgE in 4 month-old GITR
+/+ (129S1 strain, white bars, empty circles) and GITR
2/2 mice (gray bars, filled circles). n=7. (B) GITR
+/+ (129S1,
white bars, empty circles) and GITR
2/2 (grey bars, filled circles) mice (n=5 per group) were immunized i.p. with 5 mgN P 28-FICOLL. Sera were
collected before (day 0) and 4 and 7 days after immunization, and NP-specific IgM and IgG3 were measured by ELISA. (C) GITR
+/+ (129S1, white bars,
empty circles) and GITR
2/2 (grey bars, filled circles) mice (n=5 per group) were immunized i.p. with 100 mgN P 36-CGG in Alum. Sera were collected at
indicated time points and NP-specific IgM, IgG1, IgG2b and IgG2a were measured by ELISA. (D) Mice described in (C) were boosted with 5 mg/ml
NP36-CGG injected i.p. 178 days after primary immunization, and sera were collected at indicated times after boost. NP-specific IgG1, IgG2b and IgG2a
were measured by ELISA (n=4 per group). Bars and circles represent geometric means and individual mice, respectively. *p,0.05; **p#0.002;
***p#0.0002.
doi:10.1371/journal.pone.0031632.g006
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+/+ (129S1, white bars) and GITR
2/2 (black bars)
mice (n=5) were fed BrdU continuously for one week. Bars represent frequency of BrdU
+ cells in naı ¨ve B220
+ (PNA
2), germinal center (GC), memory
(MC), and plasma (PC) cell compartments gated as shown in Fig. 1. Error bars represent SD. ***p#0.003. Similar results were found in mice fed BrdU
for two weeks (data not shown). (B) Schematic for the generation of GITR-deficient and sufficient mixed bone marrow chimeras. Bone marrow cells
from CD45.2 GITR
2/2 and GITR
+/+ 129S1 mice were mixed at a 1:3 ratio with bone marrow cells isolated from CD45.1 C57BL/6 SJL mice. Cell mixtures
were injected i.v. into lethally irradiated C57BL/6 mice, which were evaluated 8 weeks later. (C) Bone marrow, spleen and lymph nodes from mixed
bone marrow chimeras (n=5 per group) generated as described in (B) were analyzed by flow cytometry to determine the frequency of CD45.2
+ cells
in B cell subsets. B cell subsets were gated as described in Figs. 1 and 4. Open bars and symbols represent CD45.2
+ GITR
+/+ B cells and filled bars and
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redundant function with GITR in B cells, we think that this is
probably not the case. The reason is that when we evaluated two
of the TNF-family receptors that are the most similar to GITR,
CD27 and OX40, we found that they were not significantly
expressed on resting B cells (data not shown). More importantly,
expression of CD27 and OX40 was not significantly upregulated
on either GITR-sufficient or GITR-deficient B cells upon BCR
stimulation (data not shown), suggesting that CD27 and OX40 do
not share a redundant function with GITR in B cells.
What other role, if any, may GITR play in B cells? The fact that
expression of GITR on B cells is positively regulated by BCR
stimulation and negatively regulated by factors provided by helper
T cells suggests that GITR may function to discriminate the
response of B cells that receive signal 1 (antigen) in the absence of
signal 2 (e.g., T cell help, inflammatory cytokines) from that of B
cells that receive both signals. For instance, GITR may be
important in the context of B cell tolerance to self-antigens.
Presently, this seems unlikely given that we were unable to detect
anti-chromatin antibodies (the most common autoantibodies
expressed when B cell tolerance is defective) in young and old
GITR
2/2 mice (data not shown). Alternatively, GITR might play
a role in B cell responses that we have not tested such as cytokine
production during immune responses, and generation of neutral-
izing antibodies during infections. Although not having a
significant role in common B cell functions, GITR may still
function as a marker to distinguish B cell subsets given that its
expression decreases in GC and memory B cells while it increases
in plasma cells relative to naı ¨ve B cells.
In conclusion, our findings indicate that, in the context of a
whole GITR
2/2 genetic background, GITR does not play a
significant role in B cell generation or antibody responses to model
antigens, but it slightly contributes to mature B cell homeostasis.
Our data, therefore, support the idea that defects in immune
responses observed in mice that lack GITR are not likely caused
by changes in B cell function.
Materials and Methods
Mice
CB17, BALB/c, 129S1/svImJ (129S1), and B6.SJL mice were
purchased from Jackson Laboratories and then bred or main-
tained in our facility. GITR-deficient (GITR
2/2) mice [16] were
imported from Italy and then bred in our facility. GITR
2/2 mice
were received and maintained on a 129SvJ genetic background.
GITR
2/2 mice were also bred to 129S1 in our facility to generate
F1 mice that were then intercrossed to obtain F2 GITR
2/2 mice.
No differences were observed between the newly derived GITR
2/
2 mice and GITR
2/2 mice derived from the original stock,
indicating no effect of genetic background. Both females and males
were used for experiments, and mice used for individual
experiments were matched for age and sex. All animals were
bred and maintained in specific pathogen-free rooms at the
Biological Research Center at National Jewish Health, Denver,
CO. All animal protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) under permit
#A3026-01.
Flow Cytometry and antibodies
Bone marrow and spleen single cells were resuspended in PBS,
3% FBS and stained with fluorochrome-conjugated or biotinylated
antibodies against B220 (RA3-6B2), IgD (11-26c-2a), IgM
a (DS-1),
CD2 (RM2-5), CD24 (M1/69), CD3 (145-2C11), CD4 (GK1.5),
CD8 (53-6.7), CD11b (M1/70), CD138 (281-2), IgG1 (A85-1),
IgG2a/2b (R2-40), CD93 (AA4.1), GITR (DTA-1), CD1d (1B1),
CD21 (7G6), CD23 (B3B4), CD69 (H1.2F3), CD86 (GL1) (all
from eBioscience or BD Pharmingen), CD19 (1D3), CD21 (7G6)
IgM (R33-24.12) and IgD (1.3–5) (generated in house). Rat IgG2b
(eBioscience) was used as isotype control for GITR staining. PNA
(FL-1071; Vector Laboratories) was used for staining germinal
center B cells. Biotin-labeled antibodies were visualized with
fluorochrome-conjugated streptavidin (eBioscience). Propidium
iodide (Sigma-Aldrich) was used is some experiments to exclude
dead cells. Data acquisition was done on a CyAn (Beckman
Coulter), Facscan (BD) or Facscalibur (BD) flow cytometer and
analyzed with FlowJo software (Tree Star). Before each analysis,
the flow cytometer was set using single color staining of each
antibody on a mix spleen cell population that contained negative
and positive cells. Cell analyses were performed on a doublet cell
excluded (single), live and lymphoid (based on forward and side
scatter) cell gate.
In vitro cell culture and cell proliferation assay
Splenic B cells were purified by negative selection using anti-
CD43 monoclonal antibody coupled to magnetic beads (Miltenyi
Biotech) and an AutoMACS (Miltenyi Biotech) according to
manufacturer’s instructions. B cell purity was consistently .90%
based on B220 or CD19 staining. Enriched B cells were cultured
at 5610
6 cells/ml for 8–72 h in the presence of 4 ng/ml
recombinant BAFF (R&D Systems) to increase B cell survival
[22]. This low amount of BAFF was added to increase B cell
survival, and did not change the parameters evaluated for B cell
activation (data not shown). Where appropriate, cells were treated
with 2 or 10 mg/ml F(ab9)2 goat anti mouse IgM antibodies
(Jackson ImmunoResearch Laboratories), 20 mg/ml LPS, 2 mM
cycloheximide, 0.1 mM actinomycin D in 0.4% dimethyl sulfoxide
(DMSO), 0.2 mM cyclosporin A in 0.2% DMSO (all from Sigma-
Aldrich), 15 mg/ml anti-CD40 antibodies (FGK 45.5), 50 ng/ml
recombinant mouse IL-4 (eBioscience), 100 and 1000 U/ml IFNc
(R&D Systems), 100 and 1000 U/ml IFNa (PBL Interferon-
Source) or 1 mg/ml GITRL. The GITRL reagent consisted of a
synthetic His-GITRL protein and anti-polyHistidine antibodies
used at 10 mg/ml (R&D Systems). In cell cultures with treatments
dissolved in DMSO, DMSO was added to control wells at the
same concentration.
For cell proliferation, splenic cells were purified over Ficoll-
Paque Premium (GE Healthcare) and labeled with 2.5 mM
Carboxyfluorescein Succinimidyl Ester (CFSE; Invitrogen Molec-
ular Probes). CFSE-labeled cells were cultured for four days in the
presence of 4 ng/ml BAFF. Additional treatments included
10 mg/ml anti-IgM antibodies, 15 mg/ml anti-CD40 antibodies
(1C10), and a combination of anti-IgM and anti-CD40 antibodies
or anti-IgM antibodies and 50 ng/ml IL-4. Agonistic anti-GITR
DTA-1 antibodies (from eBioscience or produced in house) were
added to some cultures at 10 mg/ml.
symbols represent CD45.2
+ GITR
2/2 B cells. The graphs represent means and SEM for each indicated B cell subset. (D) The relative size of the CD45.2
+
B cell population in each spleen B cell compartment was measured relative to that of the transitional B cell population in each mouse described in (C).
The bar graph represents the average fold change (+SEM) in the size of each CD45.2 B cell subset relative to the transitional B cell subset, which was
set at 1. Open bars represent CD45.2
+ GITR
+/+ B cells and filled bars represent CD45.2
+ GITR
2/2 B cells. *p,0.05.
doi:10.1371/journal.pone.0031632.g007
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Mice were immunized i.p. with 100 mgN P 36-CGG (4-Hydroxy-
3-nitrophenylacetic hapten conjugated to chicken gamma globu-
lin, Biosearch Technologies) mixed at equal volume with Alu-Gel-
S (Aluminum hydroxide, SERVA) in PBS, or with 5 mgN P 28-
FICOLL (4-Hydroxy-3-nitrophenylacetic hapten conjugated to
AminoEthylCarboxyMethyl-FICOLL, Biosearch Technologies) in
PBS. For NP-CGG boost immunizations, mice were injected with
5 mgN P 36-CGG in PBS 178 days after the first immunization.
Total serum Ig isotype levels were measured by coating 96-well
Nunc-Immuno MaxiSorp plates (Thermo Fisher Scientific) with
5 mg/ml of goat anti-mouse IgM, IgG1, IgG2b, IgG2a (South-
ernBiotech) or IgE antibodies (R35-72, BD Pharmingen). After
blocking with PBS, 1% BSA, diluted serum samples were added
and further serially diluted. Standard curves were generated by
serially diluting purified mouse IgM, IgG1, IgG2b, IgG2a
(SouthernBiotech) and IgE (BD Pharmingen). Isotype-specific
antibodies were detected using alkaline phosphatase (AP)-conju-
gated goat anti-mouse IgM, IgG1, IgG2b, IgG2a and rat anti-
mouse IgE (SouthernBiotech) antibodies, and developed by the
addition of AP substrate (p-nitrophenyl phosphate, Sigma).
NP-specific antibodies were measured as previously described
[23]. Briefly, plates were coated with 2 mg/ml NIP22-BSA
(Biosearch Technologies). After blocking as described above,
serum samples were added and serially diluted. Isotype-specific
antibodies were detected with isotype-specific AP-conjugated goat
anti-mouse Ig antibodies (SouthernBiotech) and developed with
AP substrate. Standard curves were generated using NP-specific
mouse monoclonal antibodies: B1-8m (NP-specific IgM), S24/63/
63 (NP-specific IgG3), N1G9 (NP-specific IgG1), D3-13F1 (NP-
specific IgG2b) and S43-10 (NP-specific IgG2c/a).
The absorbance values of plates were read at 405 nm on a
Versamax ELISA reader (Molecular Devices), and the data were
analyzed with SoftMax Pro 5 Software (Molecular Devices).
5-bromo-29-deoxyuridine (BrdU) incorporation
Mice were fed 0.8 mg/ml BrdU (Sigma) in water containing 1%
D-glucose ad libitum for one or two weeks. BrdU-containing water
was changed twice a week. BrdU incorporation in B cell subsets
was assessed by staining cells for appropriate surface markers and
then for BrdU using the APC BrdU Flow Kit (BD Pharmingen)
according to manufacturer’s instructions.
Generation of mixed bone marrow chimeras
Donor bone marrow cells from 129S1, GITR
2/2 or B6.SJL




staining with a cocktail of biotinylated anti-CD49 (DX5), anti-
CD3 (145-2C11) and anti-IgM (R33-24) antibodies, followed by
anti-biotin magnetic beads. Cells bearing those markers were
removed by AutoMACS (Miltenyi). Cell purity was determined to
be $97% by flow cytometric analysis of CD49, CD3, and IgM
expression. After cell depletion, 129S1 and GITR
2/2 donor cells
were mixed at 1:3 ratio with B6.SJL donor cells and injected i.v.
(1–2610
6 cells/mouse) into irradiated C57BL/6J recipient mice as
previously described [24]. Bone marrow chimeras were sacrificed
and organs harvested after 8 weeks, and B cell development and
maturation was assessed by flow cytometry.
Statistical data analysis
Data were analyzed using GraphPad Prism software. Statistical
significance was assessed with a one-tailed, unpaired Student’s t
test. P,0.05 was considered significant. Data are represented as
means 6 standard deviation (SD) or geometric means 6SEM.
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